{"id":"https://openalex.org/W3020933739","doi":"https://doi.org/10.1507/endocrj.ej19-0617","title":"A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease","display_name":"A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease","publication_year":2020,"publication_date":"2020-01-01","ids":{"openalex":"https://openalex.org/W3020933739","doi":"https://doi.org/10.1507/endocrj.ej19-0617","mag":"3020933739","pmid":"https://pubmed.ncbi.nlm.nih.gov/32378529"},"language":"en","primary_location":{"id":"doi:10.1507/endocrj.ej19-0617","doi":"https://doi.org/10.1507/endocrj.ej19-0617","is_oa":true,"landing_page_url":"https://doi.org/10.1507/endocrj.ej19-0617","pdf_url":"https://www.jstage.jst.go.jp/article/endocrj/67/8/67_EJ19-0617/_pdf","source":{"id":"https://openalex.org/S191387813","display_name":"Endocrine Journal","issn_l":"0918-8959","issn":["0918-8959","1348-4540"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","medline","norway-1","oarl","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310313267","host_organization_name":"Japan Endocrine Society","host_organization_lineage":["https://openalex.org/P4310313267"],"host_organization_lineage_names":["Japan Endocrine Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine Journal","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.jstage.jst.go.jp/article/endocrj/67/8/67_EJ19-0617/_pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035001251","display_name":"Tomoaki Tanaka","orcid":"https://orcid.org/0000-0002-9761-1750","observed_orcids":["https://orcid.org/0000-0002-9761-1750"]},"institutions":[{"id":"https://openalex.org/I159385669","display_name":"Chiba University","ror":"https://ror.org/01hjzeq58","country_code":"JP","type":"education","lineage":["https://openalex.org/I159385669"]},{"id":"https://openalex.org/I4210099339","display_name":"Chiba University Hospital","ror":"https://ror.org/0126xah18","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210099339"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomoaki Tanaka","raw_affiliation_strings":["Department of Molecular Diagnosis, Chiba University Hospital/Chiba University Graduate School of Medicine, Chiba 260-8670, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Molecular Diagnosis, Chiba University Hospital/Chiba University Graduate School of Medicine, Chiba 260-8670, Japan","institution_ids":["https://openalex.org/I159385669","https://openalex.org/I4210099339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017829907","display_name":"Fumitoshi Satoh","orcid":"https://orcid.org/0000-0003-0720-0470","observed_orcids":["https://orcid.org/0000-0003-0720-0470"]},"institutions":[{"id":"https://openalex.org/I4210093896","display_name":"Tohoku University Hospital","ror":"https://ror.org/00kcd6x60","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210093896"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Fumitoshi Satoh","raw_affiliation_strings":["Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Hospital, Sendai 980-8574, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Hospital, Sendai 980-8574, Japan","institution_ids":["https://openalex.org/I4210093896"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113335631","display_name":"Makoto Ujihara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405283918","display_name":"National Hospital Organization Yokohama Medical Center","ror":"https://ror.org/02h7rhs19","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210137409","https://openalex.org/I4405283918"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Makoto Ujihara","raw_affiliation_strings":["Department of Internal Medicine, National Hospital Organization Yokohama Medical Center, Yokohama 245-8575, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, National Hospital Organization Yokohama Medical Center, Yokohama 245-8575, Japan","institution_ids":["https://openalex.org/I4405283918"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075763432","display_name":"Sanae Midorikawa","orcid":"https://orcid.org/0000-0003-2483-888X","observed_orcids":["https://orcid.org/0000-0003-2483-888X"]},"institutions":[{"id":"https://openalex.org/I130830085","display_name":"Fukushima Medical University","ror":"https://ror.org/012eh0r35","country_code":"JP","type":"education","lineage":["https://openalex.org/I130830085"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Sanae Midorikawa","raw_affiliation_strings":["Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan","institution_ids":["https://openalex.org/I130830085"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021511833","display_name":"Tomomi Kaneko","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210105804","display_name":"Novartis (Japan)","ror":"https://ror.org/01k1ftz35","country_code":"JP","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210105804"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tomomi Kaneko","raw_affiliation_strings":["Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan","institution_ids":["https://openalex.org/I4210105804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106172064","display_name":"Tamami Takeda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210105804","display_name":"Novartis (Japan)","ror":"https://ror.org/01k1ftz35","country_code":"JP","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210105804"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tamami Takeda","raw_affiliation_strings":["Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan","institution_ids":["https://openalex.org/I4210105804"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Akina Suzuki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210105804","display_name":"Novartis (Japan)","ror":"https://ror.org/01k1ftz35","country_code":"JP","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210105804"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akina Suzuki","raw_affiliation_strings":["Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan","institution_ids":["https://openalex.org/I4210105804"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Masahiko Sato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210105804","display_name":"Novartis (Japan)","ror":"https://ror.org/01k1ftz35","country_code":"JP","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210105804"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masahiko Sato","raw_affiliation_strings":["Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan","institution_ids":["https://openalex.org/I4210105804"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049772836","display_name":"Akira Shimatsu","orcid":"https://orcid.org/0000-0002-9688-006X","observed_orcids":["https://orcid.org/0000-0002-9688-006X"]},"institutions":[{"id":"https://openalex.org/I3017590076","display_name":"Kyoto Medical Center","ror":"https://ror.org/045kb1d14","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I3017590076","https://openalex.org/I4210137409"]},{"id":"https://openalex.org/I4405254881","display_name":"Kusatsu General Hospital","ror":"https://ror.org/02btnf645","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4405254881"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akira Shimatsu","raw_affiliation_strings":["Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555/Advanced Medical Care Center, Kusatsu General Hospital, Kusatsu 525-8585, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555/Advanced Medical Care Center, Kusatsu General Hospital, Kusatsu 525-8585, Japan","institution_ids":["https://openalex.org/I3017590076","https://openalex.org/I4405254881"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.9711,"has_fulltext":true,"cited_by_count":46,"citation_normalized_percentile":{"value":0.92048432,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"67","issue":"8","first_page":"841","last_page":"852"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10832","display_name":"Pituitary Gland Disorders and Treatments","score":0.538100004196167,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10832","display_name":"Pituitary Gland Disorders and Treatments","score":0.538100004196167,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12421","display_name":"Adrenal Hormones and Disorders","score":0.29490000009536743,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11054","display_name":"Adrenal and Paraganglionic Tumors","score":0.11379999667406082,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osilodrostat","display_name":"osilodrostat","score":1.0},{"id":"https://openalex.org/keywords/11beta-hydroxylase-inhibitor","display_name":"11\u03b2-hydroxylase inhibitor","score":0.968999981880188},{"id":"https://openalex.org/keywords/endogenous-cushing-s-syndrome","display_name":"endogenous Cushing's syndrome","score":0.9629999995231628},{"id":"https://openalex.org/keywords/adrenal-tumors","display_name":"adrenal tumors","score":0.628000020980835},{"id":"https://openalex.org/keywords/adrenal-hyperplasia","display_name":"adrenal hyperplasia","score":0.9869999885559082},{"id":"https://openalex.org/keywords/ectopic-acth-syndrome","display_name":"ectopic ACTH syndrome","score":0.9919999837875366},{"id":"https://openalex.org/keywords/urinary-free-cortisol","display_name":"urinary free cortisol","score":0.9539999961853027},{"id":"https://openalex.org/keywords/adrenal-insufficiency","display_name":"adrenal insufficiency","score":0.9330000281333923},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.7149999737739563},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.6949999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.885827898979187},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6143481135368347},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5922749042510986},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5860815048217773},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5469012260437012},{"id":"https://openalex.org/C2776810848","wikidata":"https://www.wikidata.org/wiki/Q1947304","display_name":"Cushing's disease","level":3,"score":0.4946002662181854},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.46223148703575134},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.22612795233726501},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.18034294247627258},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003480","descriptor_name":"Cushing Syndrome","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047748","descriptor_name":"Pituitary ACTH Hypersecretion","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1507/endocrj.ej19-0617","doi":"https://doi.org/10.1507/endocrj.ej19-0617","is_oa":true,"landing_page_url":"https://doi.org/10.1507/endocrj.ej19-0617","pdf_url":"https://www.jstage.jst.go.jp/article/endocrj/67/8/67_EJ19-0617/_pdf","source":{"id":"https://openalex.org/S191387813","display_name":"Endocrine Journal","issn_l":"0918-8959","issn":["0918-8959","1348-4540"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","medline","norway-1","oarl","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310313267","host_organization_name":"Japan Endocrine Society","host_organization_lineage":["https://openalex.org/P4310313267"],"host_organization_lineage_names":["Japan Endocrine Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine Journal","raw_type":"journal-article"},{"id":"pmid:32378529","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32378529","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine journal","raw_type":"Clinical Trial, Phase II"},{"id":"mag:3154277303","doi":null,"is_oa":false,"landing_page_url":"https://jglobal.jst.go.jp/detail?JGLOBAL_ID=202002273814554554","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":{"id":"doi:10.1507/endocrj.ej19-0617","doi":"https://doi.org/10.1507/endocrj.ej19-0617","is_oa":true,"landing_page_url":"https://doi.org/10.1507/endocrj.ej19-0617","pdf_url":"https://www.jstage.jst.go.jp/article/endocrj/67/8/67_EJ19-0617/_pdf","source":{"id":"https://openalex.org/S191387813","display_name":"Endocrine Journal","issn_l":"0918-8959","issn":["0918-8959","1348-4540"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","medline","norway-1","oarl","poland-70","russia-white-list-3"],"host_organization":"https://openalex.org/P4310313267","host_organization_name":"Japan Endocrine Society","host_organization_lineage":["https://openalex.org/P4310313267"],"host_organization_lineage_names":["Japan Endocrine Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Endocrine Journal","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G576564837","display_name":"Elucidation of molecular pathogenesis of obesity and diabetes via mitochondrial complex and its regulatory mechanism analyses","funder_award_id":"19H03708","funder_id":"https://openalex.org/F4320334764","funder_display_name":"Japan Society for the Promotion of Science"}],"funders":[{"id":"https://openalex.org/F4320334764","display_name":"Japan Society for the Promotion of Science","ror":"https://ror.org/00hhkn466"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3020933739.pdf","grobid_xml":"https://content.openalex.org/works/W3020933739.grobid-xml"},"referenced_works_count":15,"referenced_works":["https://openalex.org/W1967820500","https://openalex.org/W2029257052","https://openalex.org/W2093593211","https://openalex.org/W2101248051","https://openalex.org/W2108458133","https://openalex.org/W2117280636","https://openalex.org/W2127952551","https://openalex.org/W2142394119","https://openalex.org/W2145652401","https://openalex.org/W2368834918","https://openalex.org/W2604251382","https://openalex.org/W2805407393","https://openalex.org/W2914765137","https://openalex.org/W2941025998","https://openalex.org/W3044765479"],"related_works":["https://openalex.org/W2117280636","https://openalex.org/W3159458516","https://openalex.org/W4408482570","https://openalex.org/W2944118938","https://openalex.org/W4220667260","https://openalex.org/W3201081257","https://openalex.org/W4400081984","https://openalex.org/W4401733040","https://openalex.org/W4416438706","https://openalex.org/W4307857187"],"abstract_inverted_index":{"This":[0],"phase":[1],"2,":[2],"single-arm,":[3],"open-label,":[4],"dose-titration,":[5],"multicenter":[6],"study":[7,89,96],"evaluated":[8],"osilodrostat":[9,99,199],"(11\u03b2-hydroxylase":[10],"inhibitor)":[11],"in":[12,40,56,122,188,194,205,207,227,241],"Japanese":[13],"patients":[14,54,83,139,210,229],"with":[15,211,223,238],"endogenous":[16,212],"Cushing's":[17,216],"syndrome":[18],"(CS)":[19],"caused":[20],"by":[21,161],"adrenal":[22,169],"tumor/hyperplasia":[23],"or":[24,70],"ectopic":[25],"adrenocorticotropic":[26],"hormone":[27],"syndrome.":[28],"The":[29,233],"primary":[30],"endpoint":[31],"was":[32,101,113,124,152,236],"percent":[33],"change":[34,121],"from":[35,163],"baseline":[36],"to":[37,72,76,127,202],"week":[38,73,133,136,231],"12":[39,74,86,102],"mean":[41],"urinary":[42],"free":[43],"cortisol":[44],"(mUFC)":[45],"at":[46,69,132,230],"the":[47,52,57,61,81,245],"individual":[48],"patient":[49],"level.":[50],"Of":[51,80],"nine":[53,209],"enrolled":[55],"study,":[58],"seven":[59,82],"completed":[60,85,92],"12-week":[62],"core":[63],"treatment":[64,200],"period":[65],"and":[66,150,178,244],"two":[67,91],"discontinued":[68],"prior":[71],"due":[75],"adverse":[77],"events":[78],"(AEs).":[79],"who":[84],"weeks":[87,94],"of":[88,95,147,220],"treatment,":[90],"48":[93],"treatment.":[97],"Median":[98,104,117],"exposure":[100],"weeks.":[103],"(range)":[105],"average":[106],"dose":[107,109],"including":[108],"interruption":[110],"(0":[111],"mg/day)":[112],"2.143":[114],"(1.16-7.54)":[115],"mg/day.":[116],"(range,":[118],"population)":[119],"percentage":[120],"mUFC":[123,206],"-94.47%":[125],"(-99.0%":[126],"-52.6%,":[128],"n":[129],"=":[130,172,181],"7)":[131],"12.":[134,232],"At":[135],"12,":[137],"6/9":[138],"were":[140,168,186,248],"complete":[141],"responders":[142],"(mUFC":[143,156],"\u2264":[144],"upper":[145],"limit":[146],"normal":[148],"[ULN])":[149],"1/9":[151],"a":[153,203],"partial":[154],"responder":[155],">":[157],"ULN":[158],"but":[159],"decreased":[160],"\u226550%":[162],"baseline).":[164],"Most":[165],"frequent":[166],"AEs":[167,185,247],"insufficiency":[170],"(n":[171,180],"7),":[173],"gamma-glutamyl":[174],"transferase":[175],"increase,":[176],"malaise,":[177],"nasopharyngitis":[179],"3":[182],"each).":[183],"Serious":[184],"seen":[187,226],"four":[189],"patients.":[190],"No":[191],"deaths":[192],"occurred":[193],"this":[195],"study.":[196],"In":[197],"conclusion,":[198],"led":[201],"reduction":[204,225],"all":[208],"CS":[213],"other":[214],"than":[215],"disease":[217,221],"(CD),":[218],"regardless":[219],"type,":[222],">80%":[224],"6/7":[228],"safety":[234],"profile":[235],"consistent":[237],"previous":[239],"reports":[240],"CD":[242],"patients,":[243],"reported":[246],"manageable.":[249]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":17},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-05-13T00:00:00"}